Oncotarget

Research Papers:

DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma

Alice N. Weaver, Tiffiny S. Cooper, Marcela Rodriguez, Hoa Q. Trummell, James A. Bonner, Eben L. Rosenthal and Eddy S. Yang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:26995-27007. https://doi.org/10.18632/oncotarget.4863

Metrics: PDF 1301 views  |   HTML 1560 views  |   ?  


Abstract

Alice N. Weaver1, Tiffiny S. Cooper1, Marcela Rodriguez1, Hoa Q. Trummell1, James A. Bonner1, Eben L. Rosenthal2, Eddy S. Yang1,3,4

1Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35249, USA

2Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35249, USA

3Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35249, USA

4Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35249, USA

Correspondence to:

Eddy S. Yang, e-mail: eyang@uab.edu

Keywords: HPV, HNSCC, DNA repair, PARP inhibition

Received: May 14, 2015     Accepted: August 12, 2015     Published: August 22, 2015

ABSTRACT

Patients with human papillomavirus-positive (HPV+) head and neck squamous cell carcinomas (HNSCCs) have increased response to radio- and chemotherapy and improved overall survival, possibly due to an impaired DNA damage response. Here, we investigated the correlation between HPV status and repair of DNA damage in HNSCC cell lines. We also assessed in vitro and in vivo sensitivity to the PARP inhibitor veliparib (ABT-888) in HNSCC cell lines and an HPV+ patient xenograft. Repair of DNA double strand breaks (DSBs) was significantly delayed in HPV+ compared to HPV− HNSCCs, resulting in persistence of γH2AX foci. Although DNA repair activators 53BP1 and BRCA1 were functional in all HNSCCs, HPV+ cells showed downstream defects in both non-homologous end joining and homologous recombination repair. Specifically, HPV+ cells were deficient in protein recruitment and protein expression of DNA-Pk and BRCA2, key factors for non-homologous end joining and homologous recombination respectively. Importantly, the apparent DNA repair defect in HPV+ HNSCCs was associated with increased sensitivity to the PARP inhibitor veliparib, resulting in decreased cell survival in vitro and a 10–14 day tumor growth delay in vivo. These results support the testing of PARP inhibition in combination with DNA damaging agents as a novel therapeutic strategy for HPV+ HNSCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4863